

2 October 2026

2026 ANNUAL GENERAL MEETING – KEY DATES

In accordance with ASX Listing Rule 3.13.1, Botanix Pharmaceuticals Ltd (ASX:BOT) (“**Botanix**” or the “**Company**”) is pleased to announce the 2026 Annual General Meeting (“**AGM**”) has been scheduled for 9.30 am (AWST) on Monday, 30 November 2026 at the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth, Western Australia 6000.

An item of business at the AGM will be the re-election of directors. Nominations must be received at the Company’s registered office no later than 5.00 pm (AWST) on the closing date, Monday, 12 October 2026, being 35 business days before the AGM.

Further information on the AGM and details of the resolutions to be considered will be contained in a Notice of AGM and Explanatory Statement, which will be dispatched to shareholders prior to the meeting.

Release authorised by:

Vince Ippolito

Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: [+61 8 6555 2945](tel:+61865552945)

info@botanixpharma.com

Investor and Media Relations

Jane Morgan Management

Wilamina Russo

P: [+61 450 646 609](tel:+61450646609)

wr@janemorganmanagement.com.au